Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Conditions
Brief summary
Prostate cancer is a disease where cells in the prostate gland grow out of control. When prostate cancer has spread to other parts of the body but still responds to hormone treatment, it is called metastatic hormone-sensitive prostate cancer (mHSPC). The usual treatment for this stage of prostate cancer is hormone therapy (called androgen-deprivation therapy or ADT) combined with another medicine that blocks the effect of male hormones on cancer cells, known as an androgen-receptor pathway inhibitor. Darolutamide is a newer type of androgen-receptor inhibitor. The main goal of this study is to find out how well a combination of two treatments-darolutamide and hormone therapy (also called androgen-deprivation therapy or ADT)-works for men in Germany who have advanced prostate cancer that has spread to other parts of the body and still responds to hormone treatment. The study will look at how many men have very low or undetectable levels of a protein called prostate-specific antigen (PSA) in their blood after 12 months of treatment. PSA is a marker that doctors use to check how active prostate cancer is. The study will also look at how long men live after starting this treatment, and will collect information about their health, the type of prostate cancer they have, and any other medicines they are taking. The study will last for 5 years. At the start of the study, the study doctor will collect information about each patient's background, such as age, other health problems, and details about their prostate cancer. This information will be taken from the patient's medical records if available. If some information is missing, the doctor may ask the patient directly. Other information will be collected as the study goes on. This includes details about the patient's treatment, how they are doing during their regular medical visits, and any changes in their health. These check-ups and data collection will happen as part of the patient's usual care, including at the beginning of treatment, during treatment visits, follow-up visits, and at the end of the study observation period.
Interventions
DRUGdarolutamide plus ADT treatment
2\*300 mg darolutamide twice daily + ADT treatment
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male patients aged ≥ 18 years * Diagnosis of mHSPC with histological or cytological evidence for adenocarcinoma of prostate * Metastatic disease by conventional or new generation imaging * Physician decision to initiate treatment with Darolutamide+ADT was made as per investigator's routine treatment practice prior to enrollment in the study * Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).
Exclusion criteria
* Darolutamide treatment started more than 30 days prior to study enrollment * ADT treatment started more than 12 weeks before the start of treatment with darolutamide plus ADT * Hypersensitivity to darolutamide or any other excipient * Other prior systemic hormonal or anti-cancer treatment for mHSPC * Participation in an investigational program for prostate cancer with interventions outside of routine clinical practice
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with PSA < 0.2 ng/mL | 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of deaths or participants with end of observation | up to 60 months | — |
| Number of participants with PSA < 0.2 ng/mL | 3, 6, and 9 months | — |
| Number of participants with certain demographic characteristics | at study start | * age * race |
| Number of participants with certain clinical characteristics | at study start | * comorbities * Gleason score/ISUP * PSA prior therapy * prostate cancer volume and risk * type of metastatic disease * ECOG performance |
| Number of participants with certain testosterone value | at study start | — |
| Duration of Darolutamide+ADT treatment | up to 60 months | — |
| Timing of Darolutamide+ADT treatment start | up to 60 months | — |
| Kind of ADT treatment | up to 60 months | — |
| Number of participants who change ADT treatment | up to 60 months | — |
| Number of participants who change dosage of Darolutamide treatment | up to 60 months | — |
| Number of participants with certain reasons for darolutamide plus ADT treatment discontinuation | up to 60 months | — |
| Number of participants with certain subsequent anti-cancer therapies | up to 60 months | — |
| Number of participants with treatment-emergent adverse events | from start of treatment up to 60 months | — |
| Number of participants with certain concomitant medication at study start and changes during treatment with darolutamide plus ADT | up to 60 months | — |
Countries
Germany
Contacts
CONTACTBayer Clinical Trials Contact
Outcome results
None listed